Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

• Sponsor: University of California, Irvine (Other)
• Overall Status: Withdrawn
• CT.gov ID: NCT00581503
• Collaborator: Beckman Laser Institute University of California Irvine (Other)
• Enrollment: 0
• Locations: 2
• Duration (Months): 136
• Patients Per Site: 0
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

This study has been designed to utilize already obtained biopsy specimens for investigation of the utility of a new, non-invasive optical diagnostic technique. The study will allow a careful correlation between the Optical coherence tomography findings and conventional histology.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer; Pleural Cancer; Prostate Cancer	Device: diagnostic

Detailed Description

Optical coherence tomography is a non-invasive diagnostic technique that can provide information about tissue abnormalities, change in structure of an organ. This technique uses a near-infrared diode to emit light that can produce images of the specimen under investigation without causing damage or alterations.

Study Design

• Study Type: Observational
• Actual Enrollment: 0 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
• Study Start Date: Mar 1, 2007
• Anticipated Primary Completion Date: Jul 1, 2018
• Anticipated Study Completion Date: Jul 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
diagnostic oct imaging	Device: diagnostic; oct imaging

Outcome Measures

Primary Outcome Measures

1. Pathology results. [30 minutes]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Adult 18 years and older

• Having procedure of endobronchial, transbronchial, and / or pleural biopsy

Exclusion Criteria:

• Currently participating in any other investigational drug or device evaluation.

• Currently taking drugs that are sensitive to light.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Pulmonary and Critical Care Medicine, UCI Medical Center	Orange	California	United States	92868
2	Urology department, UCI Medical Center	Orange	California	United States	92868

Sponsors and Collaborators

• University of California, Irvine
• Beckman Laser Institute University of California Irvine

Investigators

• Principal Investigator: Matthew Brenner, M.D, Beckman Laser Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Beckman Laser Institute and Medical Center, Matthew Brenner, M.D.,Department of Pulmonary and Critical Care Medicine, University of California, Irvine
• ClinicalTrials.gov Identifier: NCT00581503
• Other Study ID Numbers: NIH/LAMMP-2006-4981
• First Posted: Dec 27, 2007
• Last Update Posted: Feb 14, 2018
• Last Verified: Feb 1, 2018

• Keywords provided by Beckman Laser Institute and Medical Center, Matthew Brenner, M.D.,Department of Pulmonary and Critical Care Medicine, University of California, Irvine: early detection of lung and pleural cancer; early detection of prostate cancer
• Additional relevant MeSH terms: Prostatic Neoplasms

Study Results

No Results Posted as of Feb 14, 2018